DOI: 10.1164/rccm.201711-2313LE
,
,
PMID: 29241016
MEDLINE Status: Publisher
Issn Electronic: 1535-4970
Reply to: Increased Propensity for Pneumonia with Fluticasone in COPD.
David A Lipson; Helen Barnacle; Ruby Birk; Noushin Brealey; Nicholas Locantore; David A Lomas; Andrea Ludwig-Sengpiel; Rajat Mohindra; Maggie Tabberer; Chang-Qing Zhu; Steven J Pascoe
Author Information: GSK, King of Prussia, Pennsylvania, United States.; GSK, Uxbridge, United Kingdom of Great Britain and Northern Ireland ; helen@thebarnacles.co.uk.; GSK, Uxbridge, United Kingdom of Great Britain and Northern Ireland ; ruby.k.birk@gsk.com.; GSK, Uxbridge, United Kingdom of Great Britain and Northern Ireland ; noushin.s.brealey@gsk.com.; GSK, King of Prussia, Pennsylvania, United States ; nicholas.w.locantore@gsk.com.; UCL Respiratory, University College London, London, United Kingdom of Great Britain and Northern Ireland ; d.lomas@ucl.ac.uk.; KLB Health Research, Lübeck, Germany ; a.ludwig@klb-healthresearch.com.; GSK, Uxbridge, United Kingdom of Great Britain and Northern Ireland ; mohindra.rajat@gmail.com.; GSK, Uxbridge, United Kingdom of Great Britain and Northern Ireland ; margaret.x.tabberer@gsk.com.; GSK, Uxbridge, United Kingdom of Great Britain and Northern Ireland ; chang-qing.2.zhu@gsk.com.; GSK, King of Prussia, Pennsylvania, United States ; steven.j.pascoe@gsk.com.
Checking for direct PDF access through Ovid |
Abstract
Abstract unavailable for this article.